WallStSmart

Merck & Company Inc (MRK)vsOption Care Health Inc (OPCH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1069% more annual revenue ($66.57B vs $5.69B). MRK leads profitability with a 4.8% profit margin vs 3.7%. OPCH appears more attractively valued with a PEG of 1.16. OPCH earns a higher WallStSmart Score of 60/100 (C).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

OPCH

Buy

60

out of 100

Grade: C

Growth: 6.0Profit: 6.0Value: 6.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.85
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$144.85

$62.01 premium

UndervaluedFair: $82.84Overvalued
OPCHFair Value (-0.1%)

Margin of Safety

-0.1%

Fair Value

$34.63

Current Price

$23.48

$11.15 premium

UndervaluedFair: $34.63Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

OPCH2 strengths · Avg: 8.0/10
P/E RatioValuation
18.0x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

OPCH4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
1.9%4/10

1.9% revenue growth

Profit MarginProfitability
3.7%3/10

3.7% margin — thin

Debt/EquityHealth
1.013/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : OPCH

The strongest argument for OPCH centers on P/E Ratio, Price/Book. PEG of 1.16 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : OPCH

The primary concerns for OPCH are Revenue Growth, Profit Margin, Debt/Equity. Thin 3.7% margins leave little buffer for downturns.

Key Dynamics to Monitor

OPCH carries more volatility with a beta of 0.61 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

OPCH scores higher overall (60/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Option Care Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Option Care Health, Inc. offers infusion services at home and at alternative sites in the United States. The company is headquartered in Bannockburn, Illinois.

Want to dig deeper into these stocks?